1. Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118. https://doi.org/10.1101/cshperspect.a033118 https://pubmed.ncbi.nlm.nih.gov/28716886 
2. Kovacs GG. Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci. 2016;17(2):189. https://doi.org/10.3390/ijms17020189 https://pubmed.ncbi.nlm.nih.gov/26848654 
3. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al.; Contributors. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-62. https://doi.org/10.1016/j.jalz.2018.02.018 https://pubmed.ncbi.nlm.nih.gov/29653606 
4. Vanderschaeghe G, Schaeverbeke J, Bruffaerts R, Vandenberghe R, Dierickx K. Amnestic MCI patients’ experiences after disclosure of their amyloid PET result in a research context. Alzheimers Res Ther. 2017;9(1):92. https://doi.org/10.1186/s13195-017-0321-3 https://pubmed.ncbi.nlm.nih.gov/29197423 
5. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10(4):309-19. https://doi.org/10.1016/S1474-4422(11)70039-4 https://pubmed.ncbi.nlm.nih.gov/21419704 
6. Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. Aβ-amyloid and Tau Imaging in Dementia. Semin Nucl Med. 2017;47(1):75-88. https://doi.org/10.1053/j.semnuclmed.2016.09.006 https://pubmed.ncbi.nlm.nih.gov/27987560 
7. Lin EC, Alavi A. PET and PET/CT- a clinical guide. In: Lin EC, Alavi A, eds. Thieme Medical. New york: Thieme; 2009. pp. 3-11. https://doi.org/10.1055/b-002-74271 
8. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of dementia. Ann N Y Acad Sci. 2011;1228(1):81-92. https://doi.org/10.1111/j.1749-6632.2011.06015.x https://pubmed.ncbi.nlm.nih.gov/21718326 
9. Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of movement disorders. Ann N Y Acad Sci. 2011;1228(1):93-108. https://doi.org/10.1111/j.1749-6632.2011.06025.x https://pubmed.ncbi.nlm.nih.gov/21718327 
10. Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics. 2014;34(3):684-701. https://doi.org/10.1148/rg.343135065 https://pubmed.ncbi.nlm.nih.gov/24819789 
11. Herholz K. Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014;58(4):332-43. https://pubmed.ncbi.nlm.nih.gov/25391316 
12. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16. https://doi.org/10.1016/S1474-4422(12)70291-0 https://pubmed.ncbi.nlm.nih.gov/23332364 
13. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, et al.; European Association of Nuclear Medicine Neuroimaging Committee. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103-10. https://doi.org/10.1007/s00259-009-1264-0 https://pubmed.ncbi.nlm.nih.gov/19838705 
14. Antonini A, DeNotaris R. PET and SPECT functional imaging in Parkinson’s disease. Sleep Med. 2004;5(2):201-6. https://doi.org/10.1016/j.sleep.2003.10.013 https://pubmed.ncbi.nlm.nih.gov/15033144 
15. Stoessl AJ, Martin WW, McKeown MJ, Sossi V. Advances in imaging in Parkinson’s disease. Lancet Neurol. 2011;10(11):987-1001. https://doi.org/10.1016/S1474-4422(11)70214-9 https://pubmed.ncbi.nlm.nih.gov/22014434 
16. Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-β-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson’s disease. Mov Disord. 1998;13(3):438-45. https://doi.org/10.1002/mds.870130311 https://pubmed.ncbi.nlm.nih.gov/9613734 
17. Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, et al. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79(13):1314-22. https://doi.org/10.1212/WNL.0b013e31826c1b0a https://pubmed.ncbi.nlm.nih.gov/22914831 
18. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-24. https://doi.org/10.1016/S1474-4422(14)70252-2 https://pubmed.ncbi.nlm.nih.gov/25496902 
19. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-19. https://doi.org/10.1002/ana.20009 https://pubmed.ncbi.nlm.nih.gov/14991808 
20. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al.; AV45-A07 Study Group. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305(3):275-83. https://doi.org/10.1001/jama.2010.2008 https://pubmed.ncbi.nlm.nih.gov/21245183 
21. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al.; Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-74. https://doi.org/10.1016/j.jalz.2015.02.004 https://pubmed.ncbi.nlm.nih.gov/25824567 
22. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398-403. https://doi.org/10.1001/archneurol.2011.153 https://pubmed.ncbi.nlm.nih.gov/21747004 
23. Mathis CA, Lopresti BJ, Ikonomovic MD, Klunk WE. Small-molecule PET Tracers for Imaging Proteinopathies. Semin Nucl Med. 2017;47(5):553-75. https://doi.org/10.1053/j.semnuclmed.2017.06.003 https://pubmed.ncbi.nlm.nih.gov/28826526 
24. Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, et al. Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. Plos One. 2013;8(2):e55031. https://doi.org/10.1371/journal.pone.0055031 https://pubmed.ncbi.nlm.nih.gov/23405108 
25. Friston KJ, Ashburner J, Kiebel S, Nichols T, Penny WD. Statistical parametric mapping: the analysis of funtional brain images. Cambridge: Academic Press; 2007. https://doi.org/10.1016/B978-012372560-8/50002-4 
26. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238-48. https://pubmed.ncbi.nlm.nih.gov/7790950 
27. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage. 2009;45(4):1241-52. https://doi.org/10.1016/j.neuroimage.2008.12.063 https://pubmed.ncbi.nlm.nih.gov/19349238 
28. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9(2):149-58. https://doi.org/10.1016/S1474-4422(10)70002-8 https://pubmed.ncbi.nlm.nih.gov/20061183 
29. Strategija obvladovanja demence v Sloveniji do leta 2020. Available from: https://www.gov.si/assets/ministrstva/MZ/DOKUMENTI/Preventiva-in-skrb-za-zdravje/nenalezljive-bolezni/Strategija_obvladovanja_demence.pdf 
30. Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol. 2014;35(11):2030-8. https://doi.org/10.3174/ajnr.A3695 https://pubmed.ncbi.nlm.nih.gov/23945233 
31. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85-94. https://doi.org/10.1002/ana.410420114 https://pubmed.ncbi.nlm.nih.gov/9225689 
32. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390-8. https://doi.org/10.2967/jnumed.107.045385 https://pubmed.ncbi.nlm.nih.gov/18287270 
33. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med. 2005;46(10):1625-32. https://pubmed.ncbi.nlm.nih.gov/16204712 
34. Whitwell JL, Graff-Radford J, Singh TD, Drubach DA, Senjem ML, Spychalla AJ, et al. 18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies. J Nucl Med. 2017;58(4):632-8. https://doi.org/10.2967/jnumed.116.179903 https://pubmed.ncbi.nlm.nih.gov/27688479 
35. Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of ¹²³I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord. 2012;18(3):225-9. https://doi.org/10.1016/j.parkreldis.2011.09.015 https://pubmed.ncbi.nlm.nih.gov/21975260 
36. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058 https://pubmed.ncbi.nlm.nih.gov/28592453 
37. Cerami C, Dodich A, Greco L, Iannaccone S, Magnani G, Marcone A, et al. The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia. J Alzheimers Dis. 2017;55(1):183-97. https://doi.org/10.3233/JAD-160682 https://pubmed.ncbi.nlm.nih.gov/27662315 
38. Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease. J Nucl Med. 2007;48(5):704-11. https://doi.org/10.2967/jnumed.106.035691 https://pubmed.ncbi.nlm.nih.gov/17475957 
39. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638-45. https://doi.org/10.2967/jnumed.109.065870 https://pubmed.ncbi.nlm.nih.gov/19759102 
40. Ishii K, Soma T, Kono AK, Sofue K, Miyamoto N, Yoshikawa T, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer’s disease. J Nucl Med. 2007;48(5):704-11. https://doi.org/10.2967/jnumed.106.035691 https://pubmed.ncbi.nlm.nih.gov/17475957 
41. Hely M, Reid W, Adena M, Halliday G, Morris J. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008 Apr 30;23(6):837- 844. Mov Disord. 2008;23(6):837-44. https://doi.org/10.1002/mds.21956 https://pubmed.ncbi.nlm.nih.gov/18307261 
42. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14(12):1357-62. https://doi.org/10.1111/j.1468-1331.2007.01977.x https://pubmed.ncbi.nlm.nih.gov/17941855 
43. Perneczky R, Diehl-Schmid J, Pohl C, Drzezga A, Kurz A. Non-fluent progressive aphasia: cerebral metabolic patterns and brain reserve. Brain Res. 2007;1133(1):178-85. https://doi.org/10.1016/j.brainres.2006.11.054 https://pubmed.ncbi.nlm.nih.gov/17184752 
44. Salmon E, Garraux G, Delbeuck X, Collette F, Kalbe E, Zuendorf G, et al. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage. 2003;20(1):435-40. https://doi.org/10.1016/S1053-8119(03)00346-X https://pubmed.ncbi.nlm.nih.gov/14527604 
45. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130(Pt 10):2616-35. https://doi.org/10.1093/brain/awm177 https://pubmed.ncbi.nlm.nih.gov/17704526 
46. Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M, Förstl H, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging. 2007;28(1):42-50. https://doi.org/10.1016/j.neurobiolaging.2005.11.002 https://pubmed.ncbi.nlm.nih.gov/16448722 
47. Desgranges B, Matuszewski V, Piolino P, Chételat G, Mézenge F, Landeau B, et al. Anatomical and functional alterations in semantic dementia: a voxel-based MRI and PET study. Neurobiol Aging. 2007;28(12):1904-13. https://doi.org/10.1016/j.neurobiolaging.2006.08.006 https://pubmed.ncbi.nlm.nih.gov/16979268 
48. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer’s disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab. 2006;26(9):1213-21. https://doi.org/10.1038/sj.jcbfm.9600296 https://pubmed.ncbi.nlm.nih.gov/16525414 
49. Heiss WD, Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci. 2012;322(1-2):268-73. https://doi.org/10.1016/j.jns.2012.09.023 https://pubmed.ncbi.nlm.nih.gov/23043907 
50. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659-68. https://doi.org/10.1093/brain/awp191 https://pubmed.ncbi.nlm.nih.gov/19773352 
51. Rus T, Popović M, Grmek M, Ibrulj S, Zupančič Križnar N, Granda G, et al. Metabolic Biomarkers of Sporadic Creutzfeldt-Jakob Disease. In: Gregorič Kramberger M, ed. 8th Cognitive Day: Dementias and the Role of Fluid Biomarkers. Ljubljana: Center for Cognitive Imparements, Department of Neurology, Neurology Clinic, University Medical Centre Ljubljana; 2019. 
52. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1(1):15056. https://doi.org/10.1038/nrdp.2015.56 https://pubmed.ncbi.nlm.nih.gov/27188934 
53. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al.; Alzheimer’s Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain. 2010;133(11):3336-48. https://doi.org/10.1093/brain/awq277 https://pubmed.ncbi.nlm.nih.gov/20935035 
54. Petersen RC. Alzheimer’s disease: progress in prediction. Lancet Neurol. 2010;9(1):4-5. https://doi.org/10.1016/S1474-4422(09)70330-8 https://pubmed.ncbi.nlm.nih.gov/20083022 
55. Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, et al. Cerebrospinal fluid tau and amyloid-β 1-42 in patients with dementia. Brain. 2015;138(Pt 9):2716-31. https://doi.org/10.1093/brain/awv181 https://pubmed.ncbi.nlm.nih.gov/26133663 
56. Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713-723.e2. https://doi.org/10.1016/j.jalz.2013.12.023 https://pubmed.ncbi.nlm.nih.gov/24721526 
57. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50-6. https://doi.org/10.1038/nature19323 https://pubmed.ncbi.nlm.nih.gov/27582220 
58. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al.; Alzheimer’s Association; Society of Nuclear Medicine and Molecular Imaging; Amyloid Imaging Taskforce. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9(1):e-1-16. https://doi.org/10.1016/j.jalz.2013.01.002 https://pubmed.ncbi.nlm.nih.gov/23360977 
59. Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. J Nucl Med. 2016;57(8):1316-22. https://doi.org/10.2967/jnumed.116.174615 https://pubmed.ncbi.nlm.nih.gov/27481605 
60. Villemagne VL. Amyloid imaging: Past, present and future perspectives. Ageing Res Rev. 2016;30:95-106. https://doi.org/10.1016/j.arr.2016.01.005 https://pubmed.ncbi.nlm.nih.gov/26827784 
61. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al.; AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-78. https://doi.org/10.1016/S1474-4422(12)70142-4 https://pubmed.ncbi.nlm.nih.gov/22749065 
62. Charidimou A, Farid K, Tsai HH, Tsai LK, Yen RF, Baron JC. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry. 2018;89(4):410-7. https://doi.org/10.1136/jnnp-2017-316851 https://pubmed.ncbi.nlm.nih.gov/29070646 
63. Kantarci K, Lowe VJ, Boeve BF, Senjem ML, Tosakulwong N, Lesnick TG, et al. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol. 2017;81(1):58-67. https://doi.org/10.1002/ana.24825 https://pubmed.ncbi.nlm.nih.gov/27863444 
64. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-601. https://doi.org/10.1002/mds.26424 https://pubmed.ncbi.nlm.nih.gov/26474316 
65. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-6. https://doi.org/10.1212/01.wnl.0000324625.00404.15 https://pubmed.ncbi.nlm.nih.gov/18725592 
66. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. https://doi.org/10.1212/WNL.47.1.1 https://pubmed.ncbi.nlm.nih.gov/8710059 
67. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. https://doi.org/10.1212/WNL.0b013e31827f0fd1 https://pubmed.ncbi.nlm.nih.gov/23359374 
68. Isaacson SH, Fisher S, Gupta F, Hermanowicz N, Kremens DE, Lew MF, et al. Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective. Expert Rev Neurother. 2017;17(3):219-25. https://doi.org/10.1080/14737175.2017.1256205 https://pubmed.ncbi.nlm.nih.gov/27813429 
69. Flisar D, Puklavec L, Grmek M, Trošt M. Slikanje SPECT dopaminskega prenašalca pri boleznih možganov. Zdr Vestn. 2008;77:635-40. 
70. Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. J Neuroimaging. 2012;22(3):225-30. https://doi.org/10.1111/j.1552-6569.2011.00583.x https://pubmed.ncbi.nlm.nih.gov/21410815 
71. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu ÖL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-50. https://doi.org/10.1007/s00259-009-1267-x https://pubmed.ncbi.nlm.nih.gov/19838702 
72. Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol. 2011;95(4):614-28. https://doi.org/10.1016/j.pneurobio.2011.08.009 https://pubmed.ncbi.nlm.nih.gov/21896306 
73. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, et al. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages. Brain Struct Funct. 2010;214(4):303-17. https://doi.org/10.1007/s00429-010-0246-0 https://pubmed.ncbi.nlm.nih.gov/20361208 
74. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007;27(3):597-605. https://doi.org/10.1038/sj.jcbfm.9600358 https://pubmed.ncbi.nlm.nih.gov/16804550 
75. Tomše P, Jensterle L, Grmek M, Zaletel K, Pirtošek Z, Dhawan V, et al. Abnormal metabolic brain network associated with Parkinson’s disease: replication on a new European sample. Neuroradiology. 2017;59(5):507-15. https://doi.org/10.1007/s00234-017-1821-3 https://pubmed.ncbi.nlm.nih.gov/28386687 
76. Taniwaki T, Nakagawa M, Yamada T, Yoshida T, Ohyagi Y, Sasaki M, et al. Cerebral metabolic changes in early multiple system atrophy: a PET study. J Neurol Sci. 2002;200(1-2):79-84. https://doi.org/10.1016/S0022-510X(02)00151-X https://pubmed.ncbi.nlm.nih.gov/12127681 
77. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26(3):912-21. https://doi.org/10.1016/j.neuroimage.2005.03.012 https://pubmed.ncbi.nlm.nih.gov/15955501 
78. Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. Eur J Nucl Med Mol Imaging. 2016;43(12):2244-54. https://doi.org/10.1007/s00259-016-3464-8 https://pubmed.ncbi.nlm.nih.gov/27470326 
79. Berti V, Mosconi L, Pupi A. Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging. PET Clin. 2014;9(2):129-40. https://doi.org/10.1016/j.cpet.2013.10.006 https://pubmed.ncbi.nlm.nih.gov/24772054 
80. Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry. 2014;85(6):692-8. https://doi.org/10.1136/jnnp-2013-306285 https://pubmed.ncbi.nlm.nih.gov/24133287 
81. Heiss WD, Rosenberg GA, Thiel A, Berlot R, de Reuck J. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC Med. 2016;14(1):174. https://doi.org/10.1186/s12916-016-0725-0 https://pubmed.ncbi.nlm.nih.gov/27806705 
82. Liu S, Buch S, Chen Y, Choi HS, Dai Y, Habib C, et al. Susceptibility-weighted imaging: current status and future directions. NMR Biomed. 2017;30(4):e3552. https://doi.org/10.1002/nbm.3552 https://pubmed.ncbi.nlm.nih.gov/27192086 
83. Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord. 2012;27(1):42-53. https://doi.org/10.1002/mds.23971 https://pubmed.ncbi.nlm.nih.gov/22031173 
84. Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry. 2000;69(5):630-5. https://doi.org/10.1136/jnnp.69.5.630 https://pubmed.ncbi.nlm.nih.gov/11032615 
85. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14. https://doi.org/10.1212/WNL.0b013e31821103e6 https://pubmed.ncbi.nlm.nih.gov/21325651 
86. Massey LA, Micallef C, Paviour DC, O’Sullivan SS, Ling H, Williams DR, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2012;27(14):1754-62. https://doi.org/10.1002/mds.24968 https://pubmed.ncbi.nlm.nih.gov/22488922 
87. Dukart J, Mueller K, Horstmann A, Barthel H, Möller HE, Villringer A, et al. Combined Evaluation of FDG-PET and MRI Improves Detection and Differentiation of Dementia. PLoS One. 2011;6(3):e18111. https://doi.org/10.1371/journal.pone.0018111 https://pubmed.ncbi.nlm.nih.gov/21448435 
88. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA. 2005;102(27):9673-8. https://doi.org/10.1073/pnas.0504136102 https://pubmed.ncbi.nlm.nih.gov/15976020 
89. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):42-52. https://doi.org/10.1016/j.neuron.2009.03.024 https://pubmed.ncbi.nlm.nih.gov/19376066 
90. Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-47. https://doi.org/10.1212/WNL.0000000000002923 https://pubmed.ncbi.nlm.nih.gov/27371494 
